Anti-CGRP monoclonal antibody
Fremanezumab
Brand names: Ajovy
Adult dose
Dose: 225mg SC monthly OR 675mg SC every 3 months
Route: SC
Frequency: monthly or quarterly
Clinical pearls
- Migraine prophylaxis (≥4 migraine days/month) after failure of ≥3 oral preventives
- Specialist headache clinic
Contraindications
- Hypersensitivity
Side effects
- Injection site reactions
- Hypersensitivity (rare anaphylaxis)
Monitoring
- Headache diary
- Response by 3 months
Reference: BNF; NICE TA631/TA764; SmPC; https://bnf.nice.org.uk/drugs/fremanezumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- MIDAS (Migraine Disability Assessment) · Headache
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS